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tic modality, Well-Being Therapy, seems to be promising. 
The growth of subspecialties, such as psychooncology and 
psychodermatology, drives towards the multidisciplinary 
organization of health care to overcome artificial boundar-
ies. There have been major transformations in health care 
needs in the past decades. From psychosomatic medicine, 
a land of innovative hypotheses and trends, many indica-
tions for changes in the current practice of medicine are 
now at hand. The aim of this critical review is to outline cur-
rent and potential clinical applications of psychosomatic 
methods.  © 2016 S. Karger AG, Basel 
 Introduction 
 Psychosomatic medicine is a wide interdisciplinary 
field that is concerned with the interaction of biological, 
psychological, and social factors in regulating the balance 
between health and disease  [1–4] . It provides a concep-
tual framework for:
 1  scientific investigations on the role of psychosocial 
factors affecting individual vulnerability, course, and 
outcome of any type of medical disease;  
2   the personalized and holistic approach to the patient, 
adding psychosocial assessment to the standard medi-
cal examination; 
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 Abstract 
 Psychosomatic research has advanced over the past de-
cades in dealing with complex biopsychosocial phenomena 
and may provide new effective modalities of patient care. 
Among psychosocial variables affecting individual vulner-
ability, course, and outcome of any medical disease, the role 
of chronic stress (allostatic load/overload) has emerged as a 
crucial factor. Assessment strategies include the Diagnostic 
Criteria for Psychosomatic Research. They are presented 
here in an updated version based on insights derived from 
studies carried out so far and encompass allostatic overload, 
type A behavior, alexithymia, the spectrum of maladaptive 
illness behavior, demoralization, irritable mood, and somat-
ic symptoms secondary to a psychiatric disorder. Macro-
analysis is a helpful tool for identifying the relationships be-
tween biological and psychosocial variables and the indi-
vidual targets for medical intervention. The personalized 
and holistic approach to the patient includes integration of 
medical and psychological therapies in all phases of illness. 
In this respect, the development of a new psychotherapeu-
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3   the integration of psychological and psychiatric thera-
pies in the prevention, treatment, and rehabilitation of 
medical disease, and 
4  multidisciplinary organization of health care that 
overcomes the artificial boundaries of traditional 
medical specialties. 
 Psychosomatic research, in the past decades, has re-
sulted in an impressive body of knowledge, with contri-
butions published in all major medical journals and in 
specifically dedicated journals such as  Psychosomatic 
Medicine ,  Psychosomatics ,  Psychotherapy and Psychoso-
matics , and the  Journal of Psychosomatic Research . Its ap-
plication has generated a number of subdisciplines: psy-
chooncology, psychonephrology, psychoneuroendocri-
nology, psychoneurogastroenterology, behavioral cardi-
ology, psychoimmunology, psychodermatology, and oth-
ers, which in turn have developed clinical services, scien-
tific societies, and medical journals  [5] .
 In this context, the Diagnostic Criteria for Psychoso-
matic Research (DCPR) have helped to translate psycho-
social variables that derived from psychosomatic research 
into operational tools. The DCPR, introduced in 1995  [6] , 
were tested in various clinical settings. Their value in the 
psychosomatic assessment, regardless of the ‘organic’ or 
‘functional’ nature of the illness, has been largely docu-
mented  [7–9] . 
 The aim of this critical review is to outline current and 
potential clinical applications of psychosomatic methods. 
It includes contributions, particularly from review arti-
cles, that are most relevant to clinical practice. For the 
first time, the DCPR are reported in a revised version 
based on insights derived from their use in a large number 
of patients and settings  [7, 8] . This version includes the 
diagnostic criteria for two additional syndromes, allostat-
ic overload and hypochondriasis. The DCPR will be de-
scribed in relation to the clinical domains to which they 
pertain ( fig. 1 ).
 Issues concerned with disciplines related to psychoso-
matic medicine, such as behavioral medicine  [10] , health 
psychology  [11] , and mind-body medicine  [12, 13] , are 
not included in this paper.
 Psychosocial Factors and Individual Vulnerability 
 A number of factors have been implied to modulate 
individual vulnerability to disease.
 Life Events and Allostatic Load 
 The role of early developmental factors in the suscep-
tibility to disease has been a frequent object of psychoso-
matic investigation  [14] . Using animal models, events 
such as premature separation from the mother have con-
sistently resulted in pathophysiological modifications, 
mainly an increased HPA axis activation  [15] . They may 
render the human individual more vulnerable to the ef-
fects of stress later in life. There has been also consider-
able interest in the association of physical and sexual 
abuse in childhood with medical disorders later in life,
yet the evidence currently available does not allow any 
firm conclusion  [14] . Children exposed to maltreatment 
showed changes (smaller volume of the prefrontal cortex, 
increased activation of the HPA axis, and elevation in lev-
els of inflammation) that persisted in adult age  [16] .
 That stressful life events may be followed by ill health 
has been a common clinical observation. The introduc-
tion of structured methods of data collection and control 
groups has allowed substantiation of the link between life 
events in the year preceding the onset of symptoms
and a number of medical disorders, encompassing endo-
crine, cardiovascular, respiratory, gastrointestinal, auto-
immune, skin, and neoplastic disease  [17–19] . Indeed, 
within a multifactorial frame of reference, stressful life 
events may affect the regulatory mechanisms of neuroen-
Allostatic overload  Stress 
Type A behavior 
Alexithymia
Personality
Hypochondriasis
Disease phobia 
Thanatophobia
Health anxiety 
Persistent somatization 
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Anniversary reaction 
Illness denial 
Illness behavior 
Demoralization 
Irritable mood 
Secondary somatic symptoms 
Psychological
manifestations
 Fig. 1. DCPR, revised version. 
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docrine-immune functions in a number of ways  [17–19] . 
Stress at large may result in responses mediated by a va-
riety of neurotransmitters, proinflammatory cytokines, 
and hormones  [20, 21] , both in the brain and the periph-
ery. In turn, chronic inflammation may play a key role in 
the pathogenesis of major disorders such as diabetes, car-
diovascular disease, and cancer  [22, 23] . 
 On the other hand, subtle and long-standing life situ-
ations should not too readily be dismissed as minor and 
negligible, since chronic, daily life stresses may be expe-
rienced by the individual as taxing or exceeding his/her 
coping skills. McEwen  [15] proposed a formulation of
the relationship between stress and the processes leading 
to disease based on the concept of allostasis, the ability of 
the organism to achieve stability through change. In this 
view, allostatic load reflects the cumulative effects of 
stressful experiences in daily life. When the cost of chron-
ic exposure to fluctuating and heightened neural or neu-
roendocrine responses exceeds the coping resources of an 
individual, allostatic overload ensues. Allostatic overload 
can be assessed by specific clinimetric criteria  [24] that 
underwent validation  [25–28] . They are now included in 
the revised version of the DCPR ( table 1 ).
 Biological parameters of allostatic load have been 
linked to cognitive and physical functioning and mortal-
ity  [15, 29] . Regions of the prefrontal cortex, hippocam-
pus, and amygdala are particularly affected  [30] .
 Health Attitudes and Behavior 
 Behaviors relevant to health mainly relate to physical 
activity, diet, sleep, smoking, drinking, and drug con-
sumption. These behavioral factors are interrelated and 
can have a synergistic effect on morbidity and mortality 
 [31, 32] . However, changing the unhealthy behavior of an 
individual is always difficult. For instance, about 75% of 
patients with cardiovascular diseases were unable to 
change their bad habits despite the fact that they were in-
formed about the risk factors  [33] . Similarly, knowledge 
about the risks associated with certain health-damaging 
behaviors is not necessarily associated with their avoid-
ance. A survey on young adults in 8 countries throughout 
Europe  [34] showed that those who engaged more in 
drinking and smoking were just as much aware of the 
negative consequences of these health-damaging behav-
iors as people who did not engage in such behaviors. In 
contrast, beliefs about the positive effects of health-pro-
tective behaviors were strongly associated with their prac-
tice  [34] .
 Social Support  
 The complex interplay among environmental, social, 
familial, psychological, and physiological processes is 
likely to become embodied in the brain to influence health 
throughout life  [35] . Dimensions of social relationships 
such as social network composition, social support, fre-
quency of social interactions, and the experience of lone-
liness and isolation have long been linked to aspects of 
physical and mental health  [35] . In this line, prospective 
population studies have substantiated the role of social 
support in relation to mortality, psychiatric and physical 
morbidity, recovery, and adjustment to chronic disease 
 [36] . Interventions designed to improve the social envi-
ronment and interpersonal relationships have been suc-
cessful in facilitating psychosocial adjustment to medical 
disorders  [36] .
 Psychological Well-Being 
 Several studies have suggested that positive affect plays 
a buffering role in coping with stress and has a favorable 
impact on disease course  [37, 38] . In recent years, there 
has been increasing interest in the concept of euthymia, a 
state characterized by psychological flexibility, resilience 
 Table 1.  Allostatic overload: revised version of the DCPR (criteria A and B are required)
Criterion A The presence of a current identifiable source of distress in the form of recent life events and/
or chronic stress; the stressor is judged to tax or exceed the individual coping skills when its 
full nature and full circumstances are evaluated
Criterion B The stressor is associated with 1 or more of the following 3 features, which have occurred 
within 6 months after the onset of the stressor:
(1) At least 2 of the following symptoms: difficulty falling asleep, restless sleep, early 
morning awakening, lack of energy, dizziness, generalized anxiety, irritability, sadness, 
demoralization 
(2) Significant impairment in social or occupational functioning
(3) Significant impairment in environmental mastery (feeling overwhelmed by the demands 
of everyday life)
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to stress, and lack of affective disturbances  [39] . Preclini-
cal evidence suggests that conditions of persistent stress 
may elicit a pattern of conserved transcriptional response 
to adversity, in which there is an increased expression of 
proinflammatory genes and a concurrent decreased ex-
pression of type 1 interferon innate antiviral response 
 [40] . Such a pattern has been implicated in the patho-
physiology of cancer and cardiovascular disease  [22, 41] . 
Frederickson et al.  [42] showed that individuals with high 
psychological well-being presented reduced gene expres-
sion of conserved transcriptional response to adversity, 
suggesting a potential protective role of psychological 
well-being in a number of medical disorders.
 Spirituality 
 Religiosity and spirituality (broadly defined as any 
feelings, thoughts, experiences, and behaviors that arise 
from the search for the ‘sacred’) have been a matter of 
growing interest in epidemiological research  [43] . Religi-
osity appeared to have a favorable effect on survival that 
is independent from behavioral factors, negative affect, 
and degree of social support  [43, 44] .
 Personality  
 The notion that personality variables can affect vul-
nerability to specific diseases was prevalent in the first 
phase of the development of psychosomatic medicine 
(1930–1960) and was particularly influenced by psycho-
analytic investigators who believed that personality pro-
files would underlay specific ‘psychosomatic diseases’. 
This hypothesis was not supported by subsequent re-
search  [1] . Two personality constructs that can poten-
tially affect general vulnerability to disease, type A behav-
ior ( table 2 ) and alexithymia ( table 3 ), have attracted con-
siderable attention, but their relationship with health 
issues is still controversial  [45] . Type A behavior is de-
rived from the ‘specific emotional complex’ observed in 
patients with heart conditions in the late 1950s  [46] and 
has been recognized in 36.1% of subjects at risk of coro-
nary heart disease and in 10.8% of patients with noncar-
diac diseases  [47] . Alexithymia appears to be linked to 
increased risk and worsened outcome of medical condi-
tions such as cardiovascular diseases, gastrointestinal 
disorders, cancer, and altered immune response to stress 
 [48–51] .
 Table 2.  Type A behavior: revised version of the DCPR (criterion A is required)
Criterion A At least 5 of the 9 following characteristics should be present:
(1) Excessive degree of involvement in work and other activities subject to deadlines
(2) Steady and pervasive sense of urgency
(3) Display of motor-expressive features (rapid and explosive speech, abrupt body 
movements, tensing of facial muscles, hand gestures) indicating a sense of being under 
pressure of time
(4) Hostility and cynicism
(5) Irritability
(6) Tendency to speed up physical activities
(7) Tendency to speed up mental activities
(8) High desire for achievement and recognition
(9) High competitiveness
 Table 3.  Alexithymia: revised version of the DCPR (criterion A is required)
Criterion A At least 3 of the following 6 characteristics should be present:
(1) Inability to use appropriate words to describe emotions 
(2) Tendency to describe details instead of feelings (e.g. circumstances surrounding an event 
rather than the feelings)
(3) Lack of a rich fantasy life
(4) Thought content associated more with external events rather than fantasy or emotions
(5) Unawareness of common somatic reactions that accompany the experience of a variety 
of feelings
(6) Occasional but violent and often inappropriate outbursts of affective behavior
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 Personality variables may deeply affect how a patient 
views illness, what it means to him/her, and his/her in-
teractions with others, including medical staff. The neu-
robiology of personality features, such as reward depen-
dence and novelty seeking  [52] , alexithymia  [53] , and 
type A behavior  [54] , provides valuable pathophysiolog-
ical insights into the tendency to develop symptoms and 
abnormal illness behavior in the setting of medical dis-
ease. 
 Implications for Clinical Practice 
 Assessment of psychosocial factors potentially influ-
encing individual vulnerability to illness is often omitted 
by the primary care physician or the medical specialist 
 [4] . This is the result of a reductionist approach that has 
deeply influenced medicine  [4, 11, 12, 17, 55, 56] . 
 Psychosocial variables affecting illness vulnerability 
may encompass:
 1  a temporal relationship between life events and symp-
tom onset or relapse;  
2  the presence of grief reactions, including the loss of a 
body part or bodily function;  
3  the perception by a person of an environment as ex-
ceeding his/her resources (i.e. allostatic load/over-
load). Often patients deny a relationship between 
their allostatic load and symptomatology, since they 
are unaware of the latency between stress accumula-
tion and symptom onset (‘I had bowel symptoms yes-
terday, which was an easy day at work, and not the 
previous days, which were awful’). Symptom worsen-
ing during weekends and vacation time is a common 
manifestation of this latency  [57] ;  
4  interpersonal relationships providing a buffering role 
for stress, and 
5  psychological assets and well-being. 
 This type of information may be crucial in managing 
patients with unexplained somatic symptoms  [58] , with 
difficult patient-doctor relationships  [59] , or with bor-
derline/mild hormone abnormalities (e.g. slightly elevat-
ed prolactin levels)  [60] . It may be obtained by expert 
interviewing and/or self-rating inventories and/or tech-
niques of self-observation (i.e. self-monitoring of daily 
activities and recording of the observed experiences in a 
diary)  [61] . Psychosomatic medicine has provided last-
ing contributions to improving history taking in medical 
settings  [62] .
 Psychosomatic Assessment and Individualized Care 
 The unified concept of health and disease of Engel  [55, 
63] allowed illness to be viewed as the result of interacting 
mechanisms at the cellular, tissue, organismic, interper-
sonal, and environmental levels. Hinkle  [64] in 1967 add-
ed human ecology as a core characterization of psychoso-
matic medicine, anticipating ecological issues such as the 
growing importance of environmental toxic factors and 
the social inequalities that affect health  [65] . 
 Tinetti and Fried  [66] suggested that the aim of the 
treatment should be the attainment of individual goals 
and the identification of all modifiable biological and 
nonbiological factors and pointed out: ‘A primary focus 
on disease, given the changed health needs of patients, 
inadvertently leads to under-treatment, overtreatment, 
or mistreatment’  [66] . 
 The psychosomatic evaluation includes important 
psychosocial variables according to clinimetric principles 
 [67–73] . The term ‘clinimetrics’ was introduced by a sup-
porter of the psychosomatic movement, Alvan R. Fein-
stein, in 1982, to indicate a domain concerned with in-
dexes, rating scales, and other expressions that are used 
to describe or measure symptoms, physical signs, and 
other clinical phenomena  [67] . The psychosomatic ap-
proach requires a comprehensive assessment, satisfactory 
patient-doctor interaction, and the application of indi-
vidualized care  [5, 61, 74] .
 Quality of Life and Patient-Reported Outcomes 
 Psychosomatic medicine pioneered the self-rated eval-
uation of psychological status in medical conditions  [61] . 
Rating scales such as the Symptom Check List 90  [75] , the 
Hospital Anxiety and Depression Scale  [76] , and the 
Symptom Questionnaire  [77] were extensively used in 
medical settings  [68, 78] . Evaluations of distress and well-
being anticipated interest in quality of life assessments 
and patient-reported outcomes. While there is neither a 
precise nor an agreed definition of quality of life, research 
in this area seeks essentially two kinds of information: the 
functional status of the individual and the patient’s ap-
praisal of his/her own health. Indeed, the subjective per-
ception of health status (e.g. lack of well-being, demoral-
ization, difficulties fulfilling personal and family respon-
sibilities) is as valid as that of the clinician in evaluating 
outcomes  [79–81] . The recent emphasis on patient-re-
ported outcomes, any report coming directly from pa-
tients about how they function or feel in relation to a 
health condition or its therapy  [82, 83] , is in line with the 
psychosomatic and clinimetric approach  [84] .
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 Illness Behavior 
 Mechanic and Volkart  [85] defined illness behavior as 
‘the ways in which given symptoms may be differentially 
perceived, evaluated, and acted (or not acted) upon by 
different kinds of persons’. Subsequently, Mechanic  [86] 
provided the following specification: ‘Illness behavior re-
fers to the varying ways individuals respond to bodily in-
dications, how they monitor internal states, define and 
interpret symptoms, make attributions, take remedial ac-
tions and utilize various sources of informal and formal 
care.’ In the past decades, new lines of research have been 
concerned with illness perception, attendance at medical 
facilities, health-care-seeking behavior, and treatment 
adherence  [87, 88] .
 The simple fact that, in the presence of certain physical 
symptoms, some persons immediately seek medical help 
while others wait a long time before consulting a physi-
cian determines the likelihood of early recognition of a 
life-threatening disease and its prompt treatment and 
prognosis. Thus, illness behavior is a core characteriza-
tion in psychosomatic medicine and provides an explan-
atory model for clinical phenomena that do not find room 
in customary taxonomy  [88] .
 The clinical spectrum of illness behavior encompasses 
a number of syndromes ( fig. 1 ), including hypochondria-
sis, which was omitted in the DSM-5 classification  [89] . 
Retaining hypochondriasis ( table  4 ) is important since 
specific psychotherapeutic strategies have been devel-
oped and validated in randomized controlled trials: they 
were targeted to address resistance to reassurance, the key 
characteristic of hypochondriasis which can be favorably 
modified  [88] . 
 Disease phobia ( table 5 ) and thanatophobia ( table 6 ) 
may be components of a hypocondriacal syndrome, yet 
 Table 4.  Hypochondriasis: revised version of the DCPR (criteria A–D are required)
Criterion A Fears of having, or the idea of having, a serious disease based on misinterpretation of bodily 
symptoms 
Criterion B The preoccupations persist despite adequate medical evaluation and reassurance, with 
opportunity for discussion and clarification
Criterion C The duration of the disturbance is at least 6 months
Criterion D The preoccupations cause marked distress and/or impairment in social and occupational 
functioning
 Table 5.  Disease phobia: revised version of the DCPR (criteria A–C are required)
Criterion A Persistent, unfounded fear of suffering from a specific disease (e.g. AIDS, cancer), with 
doubts remaining despite adequate medical examination and reassurance
Criterion B Fears tend to manifest themselves in the form of attacks rather than in constant, chronic 
worries as in hypochondriasis; panic attacks may be an associated feature
Criterion C The object of fear does not change with time, and the duration of symptoms exceeds 6 
months
 Table 6.  Thanatophobia: revised version of the DCPR (criteria A–C are required)
Criterion A At least 2 attacks in the past 6 months of impending death and/or conviction of dying soon, 
without being in a threatening situation or in real danger; adequate appraisal of the situation 
and management to be followed (if any) has been provided by a physician, with an 
opportunity for discussion and clarification
Criterion B Marked and persistent fear and avoidance of news that reminds of death (e.g. funerals, 
obituary notices); exposure to these stimuli almost invariably provokes an immediate 
anxiety response
Criterion C Avoidance, anxious anticipation, and distress interfere markedly with the level of 
functioning
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they may also occur independently. Disease phobia dif-
fers from hypochondriasis in three characteristics: (1) 
fears concern a specific disease and are unlikely to be 
shifted to another disease or organ system  [88] ; (2) fears 
tend to manifest themselves in attacks rather than in con-
stant worries as in hypochondriasis  [90] , and (3) disease 
phobia often results in the avoidance of internal and ex-
ternal illness-related stimuli, while hypochondriasis usu-
ally involves reassurance-seeking or checking behaviors 
 [91] . Disease phobia was found in 19% of consultation-
liaison psychiatry patients  [92, 93] .
 Health anxiety ( table 7 ) is characterized by worries and 
attitudes concerning illness and pain that are less specific 
than in hypochondriasis and disease phobia and respond 
to medical reassurance. It frequently occurs (21–35%) 
among consultation-liaison psychiatry patients  [92, 93] .
 Persistent somatization ( table 8 ) refers to patients in 
whom somatic symptoms have clustered, probably due to 
an enhanced general sensitivity to pain and discomfort 
 [94] . For instance, findings of altered brain-gut interac-
tions, inflammation, and visceral hypersensitivity shed 
new light on the pathophysiology of irritable bowel syn-
drome  [95, 96] , and advanced brain imaging methods 
make the distinction between ‘functional’ and ‘organic’ 
increasingly blurred  [97] . Persistent somatization may be 
associated with a variety of medical disorders  [8] .
 Table 7.  Health anxiety: revised version of the DCPR (criteria A and B are required)
Criterion A A generic worry about illness, concern about pain, and bodily preoccupations (tendency to 
amplify somatic sensations) of less than 6 months’ duration
Criterion B Worries and fears readily respond to appropriate medical reassurance, even though new 
worries may ensue after some time
 Table 8.  Persistent somatization: revised version of the DCPR (criteria A and B are required)
Criterion A Functional medical syndromes (fibromyalgia, chronic fatigue, esophageal motility disorders, 
nonulcer dyspepsia, irritable bowel syndrome, atypical chest pain, overactive bladder) whose 
duration exceeds 6 months causing distress and/or seeking medical care and/or resulting in 
impaired quality of life
Criterion B Symptoms of autonomic arousal involving other organ systems (e.g. palpitations, tremor, 
flushing, sweating) and/or exaggerated side effects from medical therapy, indicating low 
threshold of pain sensation and/or high suggestibility
 Table 9.  Conversion symptoms: revised version of the DCPR (criteria A–C are required)
Criterion A One or more symptoms or deficits affecting voluntary motor or sensory function 
characterized by lack of anatomical or physiological plausibility and/or absence of expected 
physical signs or laboratory findings and/or inconsistent clinical manifestations; if 
autonomic arousal or persistent bodily symptoms are present, conversion symptoms should 
be prominent and cause distress and/or seeking medical care and/or impaired quality of life
Criterion B Appropriate medical evaluation uncovers no organic pathology to account for the physical 
complaints
Criterion C At least 2 of the following 4 characteristics should be present:
(1) Ambivalence in reporting of symptoms (e.g. the patient appears relaxed or unconcerned 
as he/she describes distressing symptoms)
(2) Histrionic personality features (colorful and dramatic expressions, language and 
appearance, demanding dependency, high suggestibility, rapid mood changes)
(3) Precipitation of symptoms by psychological stress (the patient is unaware of such 
association)
(4) History of similar physical symptoms experienced by the patient, observed in someone 
else, or wished on someone else
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 Conversion symptoms ( table 9 ) were formulated ac-
cording to the criteria of Engel  [98] . In a sample of 1,498 
patients from various medical settings  [100] , DCPR con-
version symptoms  [6] were found in 4.5% of subjects, 
while DSM-IV conversion disorder  [99] was found in 
only 0.4%. In the same study  [100] , anniversary reaction 
( table 10 ), which is a special form of somatization or con-
version, had a prevalence of 3.6%.
 Illness denial ( table 11 ) pertains to patients who do not 
acknowledge the presence or severity of their illness. 
DCPR illness denial was found in 9% of women with 
breast cancer  [101] and in 5% of subjects who underwent 
heart transplantation  [102] .
 At variance with the DSM classification system, all the 
DCPR syndromes that connote the persistence of a mal-
adaptive mode of experiencing, perceiving, evaluating, 
and responding to one’s own health status require the fact 
that a doctor has provided an adequate appraisal of the 
situation and management to be followed (if any), with 
opportunity for discussion, negotiation, and clarification 
 [103] . If a patient has not been provided with adequate 
information about his/her medical condition and man-
agement and develops overwhelming anxiety about his/
her health, is a psychiatric diagnosis warranted as the 
DSM suggests? Is the problem caused by the patient or by 
an inadequate patient-doctor interaction?
 Demoralization and Irritable Mood 
 There is emerging awareness that psychological symp-
toms which do not reach the threshold of a psychiatric 
disorder may also affect quality of life and entail patho-
physiological and therapeutic implications. The advan-
tage of DCPR classification is that it departs from the di-
chotomy between organic and functional and from the 
misleading and dangerous assumption that if organic fac-
tors cannot be identified there must be psychological rea-
sons which fully explain the somatic symptomatology. 
The psychosomatic literature provides an endless series 
of examples where psychological factors could only par-
tially account for the unexplained medical disorder  [88] . 
In turn, the presence of an established organic cause for 
a medical disorder does not exclude but indeed increases 
the likelihood of psychological distress  [4] . In this respect, 
two syndromes in the revised DCPR, demoralization and 
irritable mood, deserve to be mentioned.
 The original DCPR definition of demoralization inte-
grated the demoralization syndrome of Frank  [104] and 
the giving up-given up complex of Schmale and Engel 
 [105] . Demoralization and major depression can be dif-
ferentiated on clinical grounds; they may occur together 
or independently, and major depression does not neces-
sarily involve demoralization  [106] . DCPR studies on de-
moralization reported very low prevalence in healthy par-
ticipants (not higher than 2–5%) and a high prevalence in 
the medically ill (about 30%)  [106] .  Table 12 shows the 
 Table 10.  Anniversary reaction: revised version of the DCPR (criteria A–C are required)
Criterion A Symptoms of autonomic arousal (e.g. palpitations, tremor, flushing, sweating) or functional 
syndromes (e.g. irritable bowel syndrome, fibromyalgia, atypical chest pain) or conversion 
symptoms causing distress and/or seeking medical care and/or impaired quality of life
Criterion B Appropriate medical evaluation uncovers no organic pathology to account for physical 
symptoms
Criterion C Symptoms began when the patient reached the age, or on the occasion of the anniversary, 
when a parent or very close family member developed a life-threatening illness and/or died; 
the patient is unaware of such association
 Table 11.  Illness denial: revised version of the DCPR (criteria A and B are required)
Criterion A Persistent denial of having a physical disorder and needing treatment (e.g. lack of 
compliance, delayed seeking of medical attention for serious and persistent symptoms, 
counterphobic behavior) as a reaction to the symptoms, signs, diagnosis, or medical 
treatment of a physical illness
Criterion B The patient has been provided with an adequate appraisal of the medical situation and 
management (if any) to be followed, with opportunity for discussion and clarification
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revised DCPR criteria for demoralization and its two dif-
ferent expressions: helplessness (the individual maintains 
the capacity to react but lacks adequate support) and 
hopelessness (when the individual feels he/she alone is 
responsible for the situation and there is nothing he/she 
or anyone else can do to overcome the problem)  [107] . 
Hopelessness/giving up is more likely to be linked to de-
pressive illness and may provide a severity connotation to 
the diagnosis of major depressive disorder. Both hope-
lessness and helplessness have been found to involve the 
serotonergic and noradrenergic systems  [108] .
 Table 13 shows the revised DCPR criteria for irritable 
mood. Irritability may be part of psychiatric syndromes; 
it is always unpleasant for the individual, and its overt 
manifestation lacks a cathartic effect  [109] . Several stud-
ies found a significant impact of irritable mood on the 
course of medical disorders as well as on the adoption of 
unhealthy lifestyles  [110–114] . Prevalence rates of DCPR 
irritable mood of about 10–15% were found in medical 
settings, including patients with myocardial infarction, 
heart transplantation, functional gastrointestinal distur-
bances, cancer, and skin diseases  [8] and up to 46% in 
patients with endocrine disorders  [115] .
 Psychiatric Disorders 
 Psychiatric illness appears to be strongly associated 
with physical diseases: mental disorders increase the risk 
for communicable and noncommunicable diseases; many 
health conditions increase the risk for mental disturbanc-
es; comorbidity complicates recognition and treatment of 
medical disorders  [116] .
 There is evidence that psychiatric disturbances in the 
course of medical disease are substantially different from 
those that can be found in psychiatric settings in terms of 
clinical characteristics, response to treatment, and prog-
nosis  [116, 117] . At times, mood and anxiety disturbanc-
es precede the onset of symptoms of a medical condition 
 [117] . The potential relationship between medical disor-
ders and psychiatric symptoms ranges from a purely co-
incidental occurrence to a direct causal role of organic 
factors. The latter may be subsumed under the rubric of 
symptomatic affective disorder whose key feature is the 
resolution of psychiatric disturbances upon specific treat-
ment of the organic condition  [118] .
 As to depression, to reach a correct diagnosis in pri-
mary care is a difficult task, and a meta-analysis  [119] in-
dicated that there are more false positives than either 
missed or correctly identified cases. Major depression has 
emerged as an extremely important source of comorbid-
ity in medical disorders. In particular:
 1  Depression may increase susceptibility to medical ill-
ness. Depression is characterized by a sustained in-
flammatory state, and increased concentrations of in-
flammatory markers might have a role in mediating 
the risk for cardiovascular and neoplastic disease  [22, 
41, 120] . It has been suggested to also be a marker of 
disease severity. For example, in pituitary-dependent 
Cushing’s disease, the presence of depression was as-
 Table 12.  Demoralization: revised version of the DCPR (criteria A and B are required; criterion C is a specifier 
for the presence of hopelessness)
Criterion A A feeling state characterized by the perception of being unable to cope with some pressing 
problems and/or of lack of adequate support from others (helplessness); the individual 
maintains the capacity to react
Criterion B The feeling state is prolonged and generalized (duration of at least 1 month)
Criterion C A feeling state characterized by the consciousness of having failed to meet expectations 
associated with the conviction that there are no solutions for current problems and 
difficulties (hopelessness)
 Table 13.  Irritable mood: revised version of the DCPR (criteria A and B are required)
Criterion A A feeling state characterized by irritability which may be experienced as brief episodes (in 
particular circumstances) or may be prolonged and generalized; it requires an increased 
effort of control over temper or results in irascible verbal or behavioral outbursts
Criterion B The experience of irritability is always unpleasant, and overt manifestations lack the 
cathartic effect of justified outbursts of anger
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sociated with the severity of the clinical presentation 
 [121] and entailed prognostic value  [122] . 
2  Medically unexplained symptoms are extremely com-
mon in medical practice. Their association with de-
pression has been consistent, regardless of the design 
of the study  [94, 123] . Depressed patients tend to have 
more somatic symptoms than nondepressed individu-
als  [94, 123] . 
3  The presence of depressive symptoms in association 
with chronic medical illness was found to affect qual-
ity of life and social functioning and lead to increased 
health care utilization  [123] . 
4  Depression was found to have an impact on compli-
ance  [124] . Many cases of ‘suicide by default’ in the 
medical population may mask a major depressive dis-
order  [125] . Examples include diabetic patients who 
stop taking insulin, those who resume strenuous work 
after myocardial infarction, and those who withdraw 
from chronic hemodialysis  [125] . 
5  Depression may be a risk factor for nonsuicide mortal-
ity  [123] , particularly in the elderly  [126] . 
 The relationship between anxiety disorders and medi-
cal illness has also been found to entail important clinical 
implications  [127–129] . The revised DCPR diagnosis of 
somatic symptoms secondary to a psychiatric disorder 
( table 14 ) acknowledges their hierarchical relationship to 
psychiatric disorders, particularly mood and anxiety dis-
turbances (e.g. symptoms of autonomic arousal may fre-
quently be a consequence of anxiety)  [130, 131] . With the 
DCPR syndrome of somatic symptoms secondary to a 
psychiatric disorder the physician formulates the hypoth-
esis that the bulk of somatic symptomatology may remit 
upon the remission of the psychiatric disorder (e.g. suc-
cessful treatment of anxiety may entail a decrease or dis-
appearance of its somatic manifestations)  [128] . 
 As discussed in detail elsewhere  [88, 132] , the DSM-5 
diagnosis of ‘somatic symptom and related disorders’ as 
well as ‘adjustment disorders’ have limited clinical utility 
in psychosomatic medicine.
 Implications for Clinical Practice 
 Emmelkamp et al.  [133] introduced the concept of 
macroanalysis (a relationship between co-occurring syn-
dromes and problems is established on the basis of where 
treatment should start first). Macroanalysis begins from 
the assumption that in most cases there are functional re-
lationships among different problem areas and that the 
targets of treatment may vary during the course of distur-
bances. The hierarchical organization that is chosen may 
depend on a variety of contingent factors (e.g. urgency, 
availability of treatment choices) that also include the pa-
tient’s preferences and priorities. Macroanalysis is a tool 
for the therapist that can also be used to inform the pa-
tient about the relationship between different problem 
areas and induce motivation to change. Macroanalysis 
should be supplemented by microanalysis: a detailed 
analysis of the onset and course of the complaints and the 
circumstances that worsen symptoms  [61] . 
 A comprehensive assessment of psychosocial aspects 
of medical disease cannot be equated to a standard psy-
chiatric evaluation  [61] and may be particularly suitable 
in the case of the following:
 1  Medically unexplained symptoms. Patients with med-
ically unexplained symptoms suffer from patterns of 
persistent bodily complaints that lack an underlying 
physical pathology despite intensive diagnostic efforts. 
Fourteen common physical symptoms are responsible 
for almost half of all primary care visits  [58, 134] , but 
only 10–15% are found to be caused by an organic ill-
ness over a 1-year period. Prevalence rates between 16 
and 32% have been reported  [135] . Medically unex-
plained symptoms cause costs in health care that are 
comparable to mental health problems like depression 
or anxiety  [135] . These patients often spend more days 
in bed than patients with severe major medical disor-
ders  [136] . 
2  Partial response to treatment/incomplete recovery. 
Quality of life may often be compromised even when 
the patient is apparently doing well. An example may 
 Table 14.  Somatic symptoms secondary to a psychiatric disorder: revised version of the DCPR (criteria A–C are 
required)
Criterion A Somatic symptoms that cause distress and/or seeking medical care and/or impaired quality 
of life
Criterion B Appropriate medical evaluation uncovers no organic pathology to account for the physical 
complaints
Criterion C A psychiatric disorder (which includes somatic symptoms within its manifestations) 
preceded the onset of somatic symptoms (e.g. panic disorder preceding cardiac symptoms)
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be provided by patients successfully treated for endo-
crine disorders and their incomplete recovery in terms 
of amelioration of quality of life  [137] . Research on 
quality of life has emphasized the discrepancies in 
health perceptions between patients, their compan-
ions, and their treating physicians  [80] .  
3  Psychiatric complications in medical illness. A timely 
identification is warranted in medical settings of psy-
chiatric disturbances which need specific treatments. 
Kornfeld  [138] illustrated that the recognition of psy-
chiatric complications, such as delirium in coronary 
care units, yielded some changes in medical care and 
organization. As important is the awareness of psychi-
atric side effects caused by medical drugs  [139] . 
4  Maladaptive illness behavior. Several manifestations 
of illness behavior (from hypochondriasis to illness de-
nial) may hinder the prevention and treatment of 
medical disorders  [87, 88] , as outlined above. 
 Integration of Psychological Care into Medical 
Treatment 
 The main levels of psychosomatic intervention are as 
follows: prevention strategies and health behavior modi-
fications, type of approach to patient care, and specific 
psychotherapeutic and psychopharmacological manage-
ment in the setting of medical disease.
 Health Behavior Modifications 
 Switching the general population to healthy lifestyles 
would be a major source of prevention for most prevalent 
conditions such as diabetes, obesity, and cardiovascular 
illness  [140–143] . Addressing the origins of disparities in 
physical and mental health care early in life may produce 
greater effects than attempting to modify health-related 
behaviors later  [144] . The exponential spending on pre-
ventive medication justified by the potential long-term 
benefits to a small segment of the population has been 
challenged  [145] , whereas the benefits of modifying life-
style by population-based measures are increasingly 
demonstrated  [145–147] . However, at present almost all 
of health care spending is directed at the traditional bio-
medically oriented care.
 General Psychosomatic Approach 
 Levels of intervention may range from reassurance 
and effective communication (whether in primary care or 
in medical specialties) to the integration of specific psy-
chotherapeutic and psychopharmacological treatments 
within the medical management  [148] . Research on psy-
chotherapy  [4] has disclosed common therapeutic ingre-
dients that may be specific or nonspecific  [4] and are rel-
evant to any physician-patient relationship ( table  15 ). 
There is experimental evidence, mainly from studies con-
cerned with placebo, that the mesolimbic dopaminergic 
system is activated when a patient expects clinical im-
provement  [108] . These findings shed new light on classic 
psychosomatic studies exploring patient-doctor interac-
tions  [149, 150] . Expectations, preferences, motivation, 
and quality of patient-doctor interactions are examples of 
variables that may affect treatment outcomes  [151–153] . 
In a pioneer study  [154] , a small amount of individual at-
tention and education (about what to expect during the 
postsurgical period) by the anesthetist resulted in a sig-
nificantly lower requirement of postsurgery analgesia and 
a shorter hospital stay compared to a control group sub-
mitted to usual postsurgical care. When these nonspe-
cific therapeutic ingredients are missing or the patient 
displays a counterproductive behavior, drugs are unlikely 
to be superior to placebo  [151–153, 155, 156] .
 Psychotherapeutic Interventions 
 Different psychotherapeutic techniques (psychoedu-
cational interventions, stress management procedures, 
cognitive-behavioral therapy, brief dynamic therapy, 
family therapy, and group interventions) have been ap-
plied to medical patients in controlled investigations 
 [147, 157–160] . Areas that have been extensively explored 
are cardiovascular  [120, 161–165] , gastrointestinal  [166] , 
 Table 15.  Nonspecific therapeutic ingredients
Full availability of the therapist for specific times Attention
Opportunity for the patient to ventilate thoughts and feelings Disclosure
An emotionally charged, confiding relationship with a helping person High arousal
A plausible explanation of the symptoms Interpretation
The active participation of patient and therapist in a ritual or procedure that is believed
by both to be the means of restoring patient health
Rituals
D
ow
nl
oa
de
d 
by
: 
93
.1
48
.1
09
.9
2 
- 1
/1
6/
20
17
 3
:1
1:
13
 P
M
 Fava/Cosci/Sonino
 
 Psychother Psychosom 2017;86:13–30 
DOI: 10.1159/000448856
24
pulmonary  [167] , neurological disorders  [168] , chronic 
pain  [169, 170] , diabetes  [171, 172] , HIV/AIDS  [173, 
174] , and cancer  [175–177] . These interventions may im-
prove lifestyle and self-management, coping, quality of 
life, distress (especially depression and anxiety), course of 
physical illness, treatment adherence, and reduction in 
utilization of medical services  [157–177] . Dealing with 
the psychological distress of family caregivers is another 
important area of action  [178] .
 For many years, abnormal illness behavior has been 
viewed mainly as an expression of personality predisposi-
tion and considered to be refractory to treatment by psy-
chotherapeutic methods, but several controlled studies 
indicated that hypochondriasis is a treatable condition by 
the use of simple cognitive strategies  [160] . 
 Another emerging area of intervention is concerned 
with strategies increasing psychological well-being in all 
phases of medical illness  [179–181] , from prevention (de-
creased well-being has been associated with unhealthy 
behaviors)  [182, 183] to rehabilitation (the process of re-
habilitation requires the promotion of well-being and 
changes in lifestyle)  [184] . Increasing well-being by Well-
Being Therapy  [179, 180] may contribute to improving 
health attitudes and behavior, either in combination with 
other therapeutic strategies or as a first-line approach.
 Psychopharmacology 
 Psychotropic drugs in the setting of medical disease 
are often employed for purposes other than psychiatric 
disorders, and most prescriptions are written by primary 
practitioners and nonpsychiatric physicians. There has 
been a very rapid increase in the prescription of antide-
pressant drugs  [185, 186] , whereas the use of benzodiaz-
epines has been relatively stable  [187–189] . 
 McEwen and Gianaros  [30] remark that sleeping pills, 
anxiolytics, and antidepressants are employed to coun-
teract manifestations of allostatic overload, but these 
agents have side effects and interactions that may be det-
rimental in the long term and do not entail a solution to 
the problems for which they are used. Any type of psy-
chotropic drug treatment, particularly after long-term 
use, may increase the risk of experiencing additional psy-
chopathology that does not necessarily subside with dis-
continuation of the drug and may modify the responsive-
ness to subsequent treatments  [190, 191] , leading to iat-
rogenic comorbidity  [139, 192, 193] . While the judicious 
use of psychotropic drugs in the medically ill may reduce 
stress, promote daytime functioning, improve mood, and 
assist in sleep induction  [194] , their prolonged utilization 
is likely to cause problems, particularly in the case of se-
lective serotonin reuptake inhibitors and serotonin nor-
adrenaline reuptake inhibitors  [191, 195] . A psychoso-
matic approach to psychotropic drug prescription thus 
applies, on an individual basis, to a careful balance be-
tween potential benefits and adverse effects  [196] .
 Implications for Clinical Practice 
 Psychosomatic medicine may have a sobering effect
on inappropriate prescriptions of psychotropic drugs in 
medical practice, with particular reference to antidepres-
sants. The basic message sold to the physicians by phar-
maceutical propaganda is that a better medical outcome 
could be obtained by treating depression, even in its mild-
er forms, with readily available medications. Depression, 
in view of its clinical implications in the prognosis of 
medical disorders regardless of its actual severity, has 
been equated to ‘bad cholesterol’ and the use of antide-
pressant drugs to statins, which should not be refused to 
anyone as a preventive or treatment measure – well be-
yond their original indications  [197] . While antidepres-
sant drugs were found to be effective for treating major 
depression in the setting of medical disease  [198, 199] , 
their actions on improving medical outcomes have not 
been demonstrated  [200, 201] and may rather involve 
side effects, interactions, and the likelihood of developing 
iatrogenic comorbidity  [118, 190, 197, 202] .
 The use of macroanalysis in medical settings may pro-
vide the ground for incorporating psychosocial strategies 
in specific clinical situations:
 1  the presence of psychological disturbances (e.g. de-
moralization, irritable mood) or of psychiatric illness 
(e.g. major depression, panic disorder); 
2  refractoriness to lifestyle modifications guided by pri-
mary care or other nonpsychiatric physicians;  
3  the presence of abnormal illness behavior (from hypo-
chondriasis to illness denial) interfering with treat-
ment or leading to frequent health care utilization, and 
4  impaired quality of life and functioning not entirely 
justified by the medical condition. 
 Multidisciplinary Care 
 There have been major transformations in health 
care needs  [66, 203, 204] . The traditional medical spe-
cialties, based mostly on organ systems (e.g. cardiology, 
gastroenterology), appear to be more and more inade-
quate in dealing with symptoms and problems which cut 
across organ system subdivisions and require a compre-
hensive approach. There are several examples around 
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the world of multidisciplinary care guided by psychoso-
matic principles.
 Psychosomatic Inpatient Units 
 Psychosomatic inpatient units are available mainly in 
Germany  [205, 206] , Japan  [207, 208] , and China  [209] . 
The characteristics of the units vary according to the type 
of health system. Their aims are to provide joint medical 
and psychological care, which would not be possible in 
traditional facilities, for the prevention and treatment of 
chronic illness and job-related disturbances (such as 
burnout)  [205] .
 Consultation-Liaison Psychiatry 
 Consultation-liaison psychiatry is a widespread mo-
dality for providing consultation in the general hospital 
 [210, 211] . It is mostly geared to treat the psychiatric com-
plications of medical illness in adults during hospitaliza-
tion. Specific geriatric and pediatric psychiatric consulta-
tion services are also available  [211, 212] . The existing 
literature indicates that the goals of consultation-liaison 
psychiatry (reducing the length of hospitalization and 
utilization of laboratory tests, providing an input on pa-
tient management, and improving social functioning af-
ter discharge) can be met, even though results consider-
ably differ across studies  [210, 213, 214] . Developments 
of consultation-liaison psychiatry are hindered by its mo-
dalities of assessment and treatment that follow a reduc-
tionist (psychiatric) paradigm, missing psychosocial per-
spectives and correlates that may affect the response to 
medical treatments  [215, 216] . 
 Medical Consultation Services within the Mental 
Health System 
 Medical comorbidity in psychiatric patients often goes 
undetected. Medical disorders may cause or exacerbate 
psychiatric disturbances  [117, 217, 218] . Psychiatrists 
tend to miss the correct medical diagnosis because they 
may fail to think of nonpsychiatric reasons for their pa-
tients’ complaints or may not have adequate instruments 
for detecting medical disorders  [117, 217] . However, spe-
cific medical consultation services (e.g. internal medi-
cine, endocrinology) within the mental health system 
have been insufficiently endorsed  [219] .
 Multidisciplinary Services 
 Multidisciplinary services have been developed within 
specialties and subspecialties such as oncology, cardiol-
ogy, dermatology, gynecology, nephrology, gastroenter-
ology, organ transplantation, and endocrinology  [219–
222] . Such services may be operated by various specialists 
(group approaches) or by a single specialist with a multi-
disciplinary background. These services address com-
plaints that fall between disciplines and require a psycho-
somatic approach. In the UK, the establishment of centers 
within the National Health System for providing psycho-
therapy to patients with anxiety and depressive disorders 
 [223] offers an example of the integration of treatments.
 Implications for Clinical Practice 
 In health care, the product is clearly health, and the 
patient is one of the producers, not just a customer  [224] . 
As a result, ‘optimally efficient health production de-
pends on a general shift of patients from their traditional 
roles as passive or adversarial consumers, to become pro-
ducers of health jointly with their health professionals’ 
 [224] .
 The partnership paradigm includes both collaborative 
care, a patient-physician relationship in which physicians 
and patients make health decisions together  [225] , and 
self-management, a plan that provides patients with 
problem-solving skills to enhance their self-efficacy  [226] .
 As Kroenke  [227] argued, neither chronic medical nor 
psychiatric disorders can be managed adequately in the 
current environment of general practice, where the typi-
cal patient must be seen in 10–15 min or less. It is ideal-
istic to pursue shared decision and self-management 
when the time for interaction is so minimal.
 Conclusions 
 The need to include consideration of function in dai-
ly life, productivity, performance of social roles, intellec-
tual capacity, emotional stability, and well-being has 
emerged as a crucial part of clinical investigation and pa-
tient care. Such awareness is far from being translated 
into operational steps in clinical practice, and the tradi-
tional outdated way of dealing with health problems still 
prevails. As Ioannidis  [228] points out, influential ran-
domized trials are generally done by and for the benefit 
of the industry, guidelines serve vested interests, and na-
tional and federal research funds are unable to address 
basic clinical questions. Even though ‘personalized med-
icine’, referred to as genomics-based knowledge, has 
promised to approach each patient as the biological indi-
vidual he/she is, the practical applications have still a 
long way to go, and neglect of psychological, behavioral, 
and social features may actually lead to a ‘depersonalized’ 
medicine  [229] .
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 From psychosomatic medicine, many indications for 
change are now at hand and could lead other medical dis-
ciplines to an overdue reappraisal of evidence-based 
medicine, whose model clashes with clinical reality and 
current health care needs.
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